Everything below concerns c-Met signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Brown fat or brown adipose tissue (BAT) is a specialized form of adipose tissue important for adaptive thermogenesis in humans and other mammals. BAT can generate heat by "uncoupling" the respiratory chain of oxidative phosphorylation within mitochondria through tissue-specific expression of uncoupling protein 1 (UCP1). BAT is primarily located around the neck and large blood vessels of the thorax, where it may effectively act in heat exchange. BAT is robustly activated upon cold exposure by the release of catecholamines from sympathetic nerves that results in UCP1 activation. Nearly half of the nerves present in adipose tissue are sensory neurons connected to the dorsal root ganglia. BAT activation may also occur in response to overfeeding. UCP1 activity is stimulated by long chain fatty acids that are produced subsequent to β-adrenergic receptor activation. UCP1 is proposed to function as a fatty acid proton symporter, although the exact mechanism has yet to be elucidated. In contrast, UCP1 is inhibited by ATP, ADP, and GTP. Attempts to simulate this process pharmacologically have so far been unsuccessful. Techniques to manipulate the differentiation of "brown fat" could become a mechanism for weight loss therapy in the future, encouraging the growth of tissue with this specialized metabolism without inducing it in other organs. A review on the eventual therapeutic targeting of brown fat to treat human obesity was published by Samuelson and Vidal-Puig in 2020.
=== Astrobiology === To understand the prospects for life to exist elsewhere in the universe, astrobiologists are interested in measuring the chemical composition of extraplanetary bodies. Because of their small size and wide-ranging functionality, microfluidic devices are suited for these remote sample analyses. From an extraterrestrial sample, the organic content can be assessed using microchip capillary electrophoresis and selective fluorescent dyes. These devices are capable of detecting amino acids, peptides, fatty acids, and simple aldehydes, ketones, and thiols. These analyses coupled together could allow detection of the key components of life, and inform the search for functioning extraterrestrial life.
Xi's administration enacted a number of changes to the structure of the CCP and state bodies, especially in a large overhaul in 2018. These reforms have been characterized by the integration of CCP and state bodies. Beginning in 2013, the CCP under Xi has created a series of Central Leading Groups: supra-ministerial steering committees, designed to bypass existing institutions when making decisions, and ostensibly make policy-making a more efficient process. Xi was also believed to have diluted the authority of premier Li Keqiang, taking authority over the economy which has generally been considered to be the domain of the premier. February 2014 oversaw the creation of the Central Leading Group for Cybersecurity and Informatization with Xi as its leader. The State Internet Information Office (SIIO), previously under the State Council Information Office (SCIO), was transferred to the central leading group and renamed in English into the Cyberspace Administration of China. As part of managing the financial system, the Financial Stability and Development Committee, a State Council body, was established in 2017. Chaired by vice premier Liu He during its existence, the committee was disestablished by the newly established Central Financial Commission during the 2023 Party and state reforms. Xi has increased the role of the Central Financial and Economic Affairs Commission at the expense of the State Council. 2018 has seen the deepening the reform of the Party and state institutions.
== Controversies == Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs. In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits. On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
This mechanism serves as a source of protection for the amino group in the amino acid. The ester will block the amino group from binding with other molecules. The last step in this reaction is the cyclization of the N-haloacylamino acids with an acetanhydride. This will result in the expected azlactone (3).
Sources: en.wikipedia.org
However, the exact age and provenance of CM 9401 remain uncertain due to a lack of detailed field documentation. In 2018, a paper describing tyrannosaurid teeth from the Two Medicine Formation noted a premaxillary tooth (YPM VPPU 023469) had a strong resemblance to the teeth of Sue to the exclusion of any Campanian tyrannosaurid. Additionally, the authors of this paper suggested that CM 9401 also comes from the Two Medicine Formation, as there were preservational similarities between its locality and the Willow Creek anticline, which is where the tooth was found. Notably, this would place both specimens in the Flag Butte Member of the Two Medicine Formation, which dates from 77 to 76.3 Ma, far older than any other Tyrannosaurus specimen, and directly contemporaneous with Daspletosaurus. In 2025, these specimens, with their old geologic age, were used as evidence by Charlie Scherer to suggest that the Tyrannosaurini did not evolve directly from Daspletosaurus.
While the review in the JB&JS was able to correlate receiving rodding surgery with greater mobility across all types of OI, in patients with type IV, the surgery did not decrease the incidence of broken bones as compared to non-rodded patients—while type IV patients with rodded tibiae experienced 0.93 tibia fractures per year, patients with natural tibiae experienced only 0.81. However, in patients with type III, rodding surgery decreased the average number of tibia fractures per year from 0.84 to 0.57.
== Names == The term lean refers to the tendency for users to have difficulty standing up straight and walking while under the influence of the drug. "Purple drank" references the mixture's typically purple hue, as the cough syrups employed are often purple in color, and the African-American Vernacular English term "drank" for an alcoholic beverage. Other names include "syrup/sizzurp", "surp/zurp", "jelly", "Tussin/Tuss'", "Barre", "Wock", "Act", "Texas tea", "mud", "dirty Sprite", and "tsikuni". In areas where lean had not yet been introduced, codeine-based cough syrup mixed with antihistamine pills was called "juice and beans". Lean is also sometimes referred to by color in slang, usually purple (usually shortened to "purp"), but can also be red, green, or yellow based on the ingredients used.
== Contraindications == Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia. Terlipressin may cause fetal harm when used during pregnancy.
These fears of subversive Peruvians were also fueled by the widely publicized kidnapping, together with the collection of a ransom of 1,000,000 dollars, of the Bolivian businessman and politician Samuel Doria Medina; a fact that was carried out by Peruvians (also classified as subversives) members of the Tupac Amaru Revolutionary Movement (MRTA). All of which were events that generated a very bad reputation for Peruvians among Bolivian society, being incited by said prejudices and stereotypes by the morbidity of the press. Despite everything, Bolivian institutions report that, in the prison population of in that country, it is not a reality that the number of Peruvian prisoners is proportionally greater than the Bolivian citizens sentenced to prison. The Commission for Human Rights and Pacification of the Congress of the Republic of Peru has come to examine multiple cases of aggressions and mistreatment in Bolivia, against Peruvian citizens, including Congresswoman Susana Díaz, after a trip to Bolivia, verified the excesses committed against Peruvian groups, coming to denounce that there is an "anti-Peruvian phobia", especially in the Desaguadero.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.